凝结芽孢杆菌活菌片联合益生菌低聚糖粉治疗妊娠期便秘的临床观察

【摘 要】 目的 观察和评价凝结芽孢杆菌活菌片（商品名：爽舒宝）联合益生菌低聚糖粉治疗妊娠期便秘的临床疗效。方法 将100例妊娠期便秘患者随机分为治疗组和对照组,治疗组60例,对照组40例,两组均给予基础治疗。其中治疗组在此基础上同时口服凝结芽孢杆菌活菌片和益生菌低聚糖粉,凝结芽孢杆菌活菌片首次2.1 g,以后1.05 g/次,3次/d;益生菌低聚糖粉10 g/次,3次/d,温水送服,疗程14 d。观察治疗前后便秘改善情况。结果 治疗组总有效率、大便频率明显高于对照组,差异有统计学意义(P<0.05 )。结论 凝结芽孢杆菌活菌片联合益生菌低聚糖粉治疗妊娠期便秘疗效显著,值得临床推广。     

酪酸梭菌活菌散在治疗手足口病中的应用

目的观察和评价酪酸梭菌活菌散治疗手足口病的临床疗效。方法将34例手足口病患儿随机分为治疗组和对照组,治疗组18例,对照组16例,2组均给予对症支持治疗。其中治疗组在治疗的同时加用酪酸梭菌活菌散,1周岁以下,0．5g／次,1周岁以上,1g／次,3次／d,温水送服。对照组不用酪酸梭菌活菌散治疗。对两组疱疹、食欲、体温变化情况及腹泻等并发症进行统计分析。结果治疗组起效时间、疱疹消失时间、食欲正常时间和体温恢复正常时间显著短于对照组,差异具有统计学意义（P〈0．05或0．01）。结论酪酸梭菌活菌散治疗手足口病疗效显著,具有积极的临床意义。     

凝结芽孢杆菌活菌片治疗妊娠期便秘的临床观察

目的 观察和评价凝结芽孢杆菌活菌片(商品名:爽舒宝)治疗妊娠期便秘的临床疗效.方法 将80例妊娠期便秘患者随机分为治疗组和对照组,治疗组和对照组均为40例,两组均给予基础治疗.其中治疗组在基础治疗的同时加用凝结芽孢杆菌活菌片,首次2.1g,以后1.05g/次,3次/d,温水送服.观察治疗前后大便次数、粪便性状,有无排便不尽及排便费力感、腹部不适、腹胀、腹痛.结果 治疗组总有效率、大便频率明显高于对照组,差异有统计学意义(P＜0.05),同时治疗组患者治疗后无腹部不适、腹胀、排便费力、排便不尽感等新症状出现,明显优于对照组.结论 凝结芽孢杆菌活菌片辅助治疗妊娠期便秘疗效显著,值得临床推广.     

凝结芽孢杆菌活菌片联合蒙脱石散治疗小儿腹泻的效果

目的探讨凝结芽孢杆菌活菌片联合蒙脱石散治疗小儿腹泻的效果。方法将我院2016年7月～2018年7月收治的96例腹泻患儿随机分为对照组和研究组,每组48例。对照组给予蒙脱石散治疗,研究组在对照组的基础上加用凝结芽孢杆菌活菌片。比较两组患儿的治疗效果与症状缓解时间。结果研究组的治疗总有效率为93.75%,优于对照组的81.25%,各项症状缓解时间均短于对照组,差异均有统计学意义(P0.05)。结论蒙脱石散联合凝结芽孢杆菌活菌片治疗小儿腹泻的效果显著,值得临床应用。     

凝结芽孢杆菌活菌片联合甲硝唑栓治疗细菌性阴道病的临床观察

目的观察凝结芽孢杆菌活菌片(商品名:爽舒宝)联合甲硝唑栓治疗细菌性阴道病的临床疗效。方法选取细菌性阴道病患者108例随机分为观察组和对照组,每组54例。两组患者均以甲硝唑栓放入阴道治疗,观察组在此基础上,口服凝结芽孢杆菌活菌片,首次6片,以后3片/次,3次/d,连用14d。观察两组患者用药后的临床疗效及不良反应,并比较治疗后随访半年内的复发率。结果观察组患者临床总有效率(90.7%)明显高于对照组(74.1%)(P0.05),治疗期间均未见明显的药物不良反应。治疗后随访半年,观察组的复发率(14.3%)明显低于对照组(32.5%)(P0.05)。结论凝结芽孢杆菌活菌片联合甲硝唑栓治疗细菌性阴道病疗效显著,能降低复发率,值得临床推广应用。     

凝结芽孢杆菌活菌片预防剖腹产术后胃肠功能紊乱的临床观察

目的 观察和评价凝结芽孢杆菌活菌片(商品名:爽舒宝)预防剖腹产术后胃肠功能紊乱的临床疗效.方法 将60例妊娠期患者随机分为预防组和对照组,预防组和对照组均为30例.其中预防组住院后开始口服凝结芽孢杆菌活菌片,首次2.1g,以后1.05 g/次,3次/d,温水送服.观察两组患者剖腹产术后便秘、腹部不适、腹胀、腹痛、食欲不振等消化道症状.结果 预防组术后首次排便时间明显短于对照组,大便频率增加,腹部不适、腹胀、排便费力等伴随症状发生率明显低于对照组(P＜0.05).结论 凝结芽孢杆菌活菌片预防剖腹产术后胃肠功能紊乱疗效显著,值得临床推广.     

凝结芽孢杆菌活菌片预防先兆流产保胎妇女胃肠功能紊乱的临床观察

目的观察凝结芽孢杆菌活菌片（商品名：爽舒宝）预防先兆流产保胎妇女胃肠功能紊乱的临床疗效。方法将60例先兆流产保胎妇女随机分为爽舒宝预防组和对照组,预防组30例,对照组30例,两组均给予常规服用保胎药物,出现顽固性便秘后用开塞露通便,其中预防组在此基础上同时口服凝结芽孢杆菌活菌片首次2. 1 g,以后1.05 g/次,3次/d,温水送服,疗程2-4周。观察保胎期间孕妇胃肠功能紊乱情况和使用开塞露的通便次数。结果预防组患者胃肠功能紊乱的发生率显著低于对照组,差异有统计学意义（P〈0.05 ）。结论凝结芽孢杆菌活菌片预防先兆流产保胎妇女胃肠功能紊乱疗效显著,值得临床推广。     

凝结芽孢杆菌活菌片预防产褥期便秘的临床观察

目的观察和评价凝结芽孢杆菌活菌片(商品名:爽舒宝)预防产褥期便秘的临床疗效。方法选取我院正常分娩(阴道分娩或剖宫产)的产妇200例,按随机数字表分为观察组和对照组,每组均为100例。观察组的100例产妇给予口服凝结芽孢杆菌活菌片,首次2.1 g,后1.05 g/次,3次/d,温水送服,疗程为14 d;对照组的100例产妇不服用任何微生态制剂药物。观察两组产妇便秘发生率和大便次数、大便量、大便性状等。结果观察组产妇便秘的发生率为15%,明显低于对照组的50%,差异有统计学意义(P<0.05);观察组产妇大便次数及大便量均明显多于对照组,大便性状明显比对照组有所改善,且无伴随症状。结论凝结芽孢杆菌活菌片预防产褥期便秘疗效显著,值得临床推广。     

凝结芽孢杆菌活菌片治疗孕妇功能性腹胀的临床疗效

目的探讨凝结芽孢杆菌活菌片(商品名:爽舒宝)治疗孕妇功能性腹胀的临床疗效。方法选取193例功能性腹胀的孕妇,随机分为治疗组和对照组,对照组指导注意饮食、加强运动等进行调理,治疗组在上述调理的基础上口服凝结芽孢杆菌活菌片,首次服用6片,以后3片/次,3次/d,疗程为4周。观察孕妇胀气、排气、排便的变化情况以及观察药物不良反应。结果治疗4周后,孕妇胀气、排气、排便情况均得到明显改善,显著优于对照组(t分别为-1.991、-2.548、-1.951,P0.05)。治疗过程中未发现药物不良反应。结论凝结芽孢杆菌活菌片治疗孕妇功能性腹胀取得了较好的疗效,安全性好,值得临床推广。     

口服凝结芽孢杆菌活菌片治疗外阴阴道假丝酵母菌病的疗效及预防复发作用

目的探讨口服凝结芽孢杆菌活菌片(商品名:爽舒宝)联合硝呋太尔制霉素阴道软胶囊治疗外阴阴道假丝酵母菌病的疗效及预防复发作用。方法选取外阴阴道假丝酵母菌病患者103例,随机分入观察组52例和对照组51例。两组患者均以硝呋太尔制霉素阴道软胶囊放入阴道,每晚1粒,连用7 d。观察组在此基础上,口服凝结芽孢杆菌活菌片,首次6片,以后3片/次,3次/d,连用14 d。观察两组患者治疗后的临床疗效及不良反应,并比较治疗后随访半年内的复发率。结果治疗后,观察组患者临床总有效率为88.5%,明显高于对照组的72.5%(χ2=4.16,P0.05),两组患者治疗中未发生明显的药物不良反应。治疗后随访半年,观察组的复发率(15.2%)明显低于对照组(37.8%)(χ2=5.55,P0.05)。结论口服凝结芽孢杆菌活菌片联合硝呋太尔制霉素阴道软胶囊用于外阴阴道假丝酵母菌病治疗中取得了较好的疗效,安全性好,并能降低其复发率,具有预防病情复发作用。     

A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility

正Dear Editor,In December 2019, a novel human coronavirus caused an epidemic of severe pneumonia(Coronavirus Disease 2019,COVID-19) in Wuhan, Hubei, China(Wu et al. 2020; Zhu et al. 2020). So far, this virus has spread to all areas of China and even to other countries. The epidemic has caused 67,102 confirmed infections with 1526 fatal cases     

Curcuminoids as inhibitors of thioredoxin reductase: A receptor based pharmacophore study with distance mapping of the active site

Curcumin is the yellow pigment of turmeric that interacts irreversibly forming an adduct with thioredoxin reductase (TrxR), an enzyme responsible for redox control of cell and defence against oxidative stress. Docking at both the active sites of TrxR was performed to compare the potency of three naturally occurring curcuminoids, namely curcumin, demethoxy curcumin and bis-demethoxy curcumin. Results show that active sites of TrxR occur at the junction of E and F chains. Volume and area of both cavities is predicted. It has been concluded by distance mapping of the most active conformations that Se atom of catalytic residue SeCYS498, is at a distance of 3.56 from C13 of demethoxy curcumin at the E chain active site, whereas C13 carbon atom forms adduct with Se atom of SeCys 498. We report that at least one methoxy group in curcuminoids is necessary for interation with catalytic residues of thioredoxin. Pharmacophore of both active sites of the TrxR receptor for curcumin and demethoxy curcumin molecules has been drawn and proposed for design and synthesis of most probable potent antiproliferative synthetic drugs.     

The structure, reproduction and taxonomy of Vidalia and Osmundaria (Rhodophyta, Rhodomelaceae)

Comprises species occurring mostly in subtidal habitats in tropical, subtropical and warm-temperate areas of the world. An analysis of the type species, V. spiralis (Sonder) Lamouroux ex J. Agardh, a species from Australia, establishes basic characters for distinguishing species in the genus. These characters are (1) branching patterns of thalli, (2) flat blades that may be spiralled on their axis, (3) width of the blade, (4) primary or secondary derivation of sterile and fertile branchlets and (5) position of sterile and fertile branchlets on the thalli. Application of the latter two characters provides an important basic method for separation of species into three major groups. Osmundaria , a genus known only in southern Australia, was studied in relation to Vidalia , and its separation from the Vidalia assemblage is not accepted. Species of Vidalia therefore are transferred to the older genus name, Osmundaria. Two new species, Osmundaria papenfussii and Osmundaria oliveae are described from Natal. Confusion in the usage of the epithet, Vidalia fimbriala Brown ex Turner has been clarified, and Vidalia gregaria Falkenberg, described as an epiphyte on Osmundaria pro/ifera Lamouroux, is revealed to be young branches of the host, Osmundaria prolifera.     

New or rare chromosome counts in Artemisia L. (Asteraceae, Anthemideae) and related genera from Kazakhstan

Fifteen chromosome counts of six Artemisia taxa and one species of each of the genera Brachanthemum, Hippolytia, Kaschgaria, Lepidolopsis and Turaniphytum are reported from Kazakhstan. Three of them are new reports, two are not consistent with previous counts and the remainder are confirmations of very scarce (one to four) earlier records. All the populations studied have the same basic chromosome number, x = 9, with ploidy levels ranging from 2x to 6x. Some correlations between ploidy level, morphological characters and distribution are noted.     

肝癌中HBV和HCV基因和抗原的分布及意义

采用原位分子杂交方法检测HCV RNA及HBV X基因;采用免疫组织化学方法研究HCV核心抗原,非结构区C33c抗原及HBxAg在肝细胞肝癌中的定位及分布.结果表明(1)HCV RNA、HBV X基因在肝细胞肝癌组织检出率分别为40%(55/136)和82%(112/136).HCV RNA定位于癌细胞的胞浆内,阳性细胞呈散在、灶状及弥漫分布三种形式;HBV X基因在肝癌细胞中的分布呈胞浆型、核型及核浆型,阳性细胞也呈上述三种分布形式;(2)HCV C33c抗原、核心抗原在肝细胞肝癌中的阳性率为81%(133/164)及86%(141/164).C33c抗原定位于癌细胞及肝细胞的胞浆内;核心抗原既定位于癌细胞核中,又可定位于胞浆中.C33c抗原阳性细胞以灶状分布为主;而核心抗原阳性细     

Comparative morphology of the carpel in the Liliaceae: Hewardieae, Petrosavieae, and Tricyrteae

The young pistils in the melanthioid tribes, Hewardieae, Petrosavieae and Tricyrteae, are uniformly tricarpellate and syncarpous. They lack raphide idioblasts. All are multiovulate, with bitegmic ovules. The Petrosavieae are marked by the presence of septal glands and incomplete syncarpy. Tepals and stamens adhere to the ovary in the Hewardieae and the Petrosavieae but not in the Tricyrteae. Two vascular bundles occur in the stamens of the Hewartlieae and Tricyrtis latifolia. Ventral bundles in the upper part of the ovary of the Hewardieae are continuous with compound septal bundles and placental bundles in the lower part. Putative ventral bundles occur in the alternate position in the Tricyrteae and putative placental bundles in the opposite. position in the Petrosavieae. The dichtomously branched stigma in each carpel of the Tricyrteae is supplied by a bifurcated dorsal bundle.